Hereditary transthyretin amyloidosis (hATTR) is a rare inherited disorder that gets worse over time. It often affects the nerves, heart, liver, and kidneys, but it can also affect other organs.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the first-ever recommendations for patient- and family-centred ...

− Phase 3b Open-Label Study Showed Treatment with Patisiran Achieved Rapid and Sustained Reduction in Serum TTR Levels in hATTR Amyloidosis Patients with Polyneuropathy Progression Following ...

Hereditary ATTR (hATTR) amyloidosis is a rare condition that affects an estimated 50,000 people worldwide. Symptoms can affect multiple parts of the body, including the nervous, cardiac and ...

Living with hATTR-PN can be challenging, both physically and emotionally. However, multiple resources can offer treatment support, financial help, and ways to connect with others. Hereditary ...

– Vutrisiran Met All 18-Month Secondary Endpoints, Including Statistically Significant Improvements in Progression of Neuropathy, Quality of Life (QOL), Gait Speed, Nutritional Status and Overall ...

CAMBRIDGE, Mass., April 21, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that data from inotersen’s clinical ...

Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) can affect many parts of the body. Nerve symptoms are often the earliest signs of this condition. hATTR-PN is a rare genetic ...

In 2023, IQWiG determined an added benefit of vutrisiran over patisiran on the basis of a study. Now the manufacturer cites the same study in the dossier on patisiran, but interprets it completely ...

The road trip trope is alive and well in medical marketing, as Alnylam Pharmaceuticals recently utilized the motif to raise awareness of hereditary ATTR (hATTR) amyloidosis. Last week, the ...